Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.Cancer Epidemiol Biomarkers Prev. 2015; 24: 298-302
- Epidemiology of GIST.in: Scoggins C.R. Raut C.P. Mullen J.T. Gastrointestinal stromal tumors: bench to bedside. Springer International Publishing, Cham2017: 7-15
- History of GIST.in: Scoggins C.R. Raut C.P. Mullen J.T. Gastrointestinal stromal tumors: bench to bedside. Springer International Publishing, Cham2017: 1-5
- Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.Science. 1998; 279: 577-580
- PDGFRA activating mutations in gastrointestinal stromal tumors.Science. 2003; 299: 708-710
- Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.Am J Surg Pathol. 2006; 30: 90-96
- Familial gastrointestinal stromal tumors and germ-line mutations.N Engl J Med. 2007; 357: 1054-1056
- Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.Genes Chromosomes Cancer. 2008; 47: 853-859
- Recurrent epimutation of SDHC in gastrointestinal stromal tumors.Sci Transl Med. 2014; 6: 268ra177
- Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.J Pathol. 2016; 238: 543-549
- FGFR1 and NTRK3 actionable alterations in "wild-type" gastrointestinal stromal tumors.J Transl Med. 2016; 14: 339
- Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.Endocr Relat Cancer. 2014; 21: 567-577
- Review of clinical next-generation sequencing.Arch Pathol Lab Med. 2017; 141: 1544-1557
- Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.J Clin Oncol. 2010; 28: 1247-1253
- Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2022; 33: 20-33
- Gastrointestinal stromal tumors (version 1.2022).(Available at:)
- Low frequency of mutation testing in the United States: an analysis of 3866 GIST patients.Am J Clin Oncol. 2020; 43: 270-278
- The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study.Virchows Arch. 2018; 472: 221-229
- Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors.JAMA Netw Open. 2020; 3e2013565
- Clinical and pathological features of "small" GIST (</=2 cm). What is their prognostic value?.Eur J Surg Oncol. 2018; 44: 580-586
- Diagnostic and treatment strategy for small gastrointestinal stromal tumors.Cancer. 2016; 122: 3110-3118
- Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.Am J Surg Pathol. 2010; 34: 1480-1491
- Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.Am J Surg Pathol. 2007; 31: 113-120
- Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA.J Gastrointest Surg. 2016; 20: 1132-1140
- Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions.Am J Surg Pathol. 2008; 32: 867-873
- Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a US population-based analysis.JAMA Surg. 2017; 152: 443-451
- Gastrointestinal stromal tumours (GIST) in young adult (18-40 years) patients: a report from the Dutch GIST Registry.Cancers (Basel). 2020; 12https://doi.org/10.3390/cancers12030730
- Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic.J Clin Oncol. 2017; 35: 523-528
- Risk stratification of patients diagnosed with gastrointestinal stromal tumor.Hum Pathol. 2008; 39: 1411-1419
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009; 373: 1097-1104
- One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.JAMA. 2012; 307: 1265-1272
- Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up.JAMA Oncol. 2020; 6: 1241-1246
- Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 Clinical Trial.JAMA Oncol. 2018; 4e184060
- Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.Ann Surg Oncol. 2013; 20: 2937-2943
- Prognostic factors after neoadjuvant imatinib for newly diagnosed primary gastrointestinal stromal tumor.J Gastrointest Surg. 2021; 25: 1828-1836
- Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: summary of 14-year clinical experience in a single center.Int J Surg. 2020; 77: 1-7
- Localized gastrointestinal stromal tumor of the rectum: an uncommon primary site with prominent disease and treatment-related morbidities.Mol Clin Oncol. 2013; 1: 190-194
- Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.Ann Surg Oncol. 2013; 20: 586-592
- Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome.Ann Surg Oncol. 2017; 24: 3972-3980
- Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: retrospective analysis of an International Patient Registry.J Surg Oncol. 2019; 120: 715-721
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med. 2002; 347: 472-480
- Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG Intergroup Trial S0033.JAMA Oncol. 2017; 3: 944-952
- Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.Ann Oncol. 2013; 24: 1087-1093
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.Lancet Oncol. 2010; 11: 942-949
- Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.BioDrugs. 2009; 23: 377-389
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.Lancet. 2006; 368: 1329-1338
- Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J Clin Oncol. 2008; 26: 5352-5359
- Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.Int J Cancer. 2011; 129: 245-255
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 295-302
- Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib.J Clin Oncol. 2020; 38: 3294-3303
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2020; 21: 923-934
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.Lancet Oncol. 2020; 21: 935-946
- Avapritinib versus regorafenib in locally advanced unresectable or metastatic gi stromal tumor: a randomized, open-label phase III study.J Clin Oncol. 2021; 39: 3128-3139
- Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med. 2018; 378: 731-739
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol. 2020; 21: 271-282
- Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.Oncoimmunology. 2019; 8e1617588
- KIT oncogene inhibition drives intratumoral macrophage M2 polarization.J Exp Med. 2013; 210: 2873-2886
- Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.Cancer Res. 2013; 73: 3499-3510
- Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.J Clin Invest. 2019; 129: 1863-1877
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Nat Med. 2011; 17: 1094-1100
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.J Clin Invest. 2004; 114: 379-388
- Oncogenic KIT modulates type I IFN-mediated antitumor immunity in GIST.Cancer Immunol Res. 2021; 9: 542-553
- Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab.Clin Cancer Res. 2017; 23: 2972-2980
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.J Immunother Cancer. 2017; 5: 35
- Overall survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med. 2017; 377: 1345-1356
- A randomized phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced gastrointestinal stromal tumors.Clin Cancer Res. 2021; https://doi.org/10.1158/1078-0432.CCR-21-0878
- PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors.Clin Cancer Res. 2017; 23: 454-465
- Macrophages and CD8(+) T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors.Cancer Immunol Res. 2018; 6: 434-447
- Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis.Ann Surg. 2018; 268: 296-302
- Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG Collaborative Study).Eur J Surg Oncol. 2014; 40: 412-419
- Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.Eur J Cancer. 2014; 50: 1772-1778
Article info
Publication history
Published online: May 31, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
